ASCO Annual Meeting

ASCO Annual Meeting

Perspective from Noopur Suresh Raje, MD
June 10, 2015
3 min read
Save

Carfilzomib significantly improves PFS in relapsed multiple myeloma

Perspective from Noopur Suresh Raje, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — A combination of carfilzomib plus dexamethasone significantly extended PFS compared with bortezomib plus dexamethasone in patients with relapsed multiple myeloma, according to the results of the phase 3 ENDEAVOR study presented at the ASCO Annual Meeting.

“Bortezomib plus dexamethasone is the standard-of-care regimen for patients with relapsed multiple myeloma, widely used throughout the world,” Meletios A. Dimopoulos, MD, chair of the department of clinical therapeutics at the University of Athens Medical School, said during a presentation. “In a phase 1b/2 study, the maximum tolerable dose of carfilzomib was 56 mg/m2 in combination with dexamethasone, and this combination showed a high response rate in relapsed and refractory multiple myeloma.”

Dimopoulos and colleagues evaluated data from 929 patients with relapsed multiple myeloma in the multi-center, open label, randomized phase 3 ENDEAVOR trial. Eligible patients underwent between one and three previous treatments for multiple myeloma.

Researchers randomly assigned patients 1:1 to a treatment regimen of carfilzomib (Kyprolis, Onyx Pharmaceuticals) plus dexamethasone (n = 464) or bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone (n = 465). Researchers stratified patients based on prior treatment with carfilzomib or bortezomib, prior line of treatment (1 vs. 2-3), International Staging System stage (1 vs. 2-3) and bortezomib route (IV vs. subcutaneous).

Patients in the carfilzomib arm received IV carfilzomib (20 mg/m2 on days 1 and 2; 56 mg/m2 thereafter) plus 20 mg dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles. Patients in the bortezomib arm received 1.3 mg/m2 IV or subcutaneous bortezomib on days 1, 4, 8, 11 and 21 plus 20 mg dexamethasone on days 1, 2, 4, 5, 8, 9, 11 and 12 in 21-day cycles.

Patients repeated treatment cycles until disease progression or unacceptable toxicity.

PFS served as the primary endpoint. OS, overall response rate (ORR), rate of peripheral neuropathy and safety served as secondary endpoints.

Median duration of treatment was 39.9 weeks for the carfilzomib arm and 26.8 weeks for the bortezomib arm.

Researchers observed significantly improved PFS among patients treated with carfilzomib compared with patients treated with bortezomib (18.7 months vs. 9.4 months; P < .0001). A significantly higher ORR occurred in the carfilzomib arm (76.9% vs. 62.6%; P < .0001).

Researchers observed a very good or better partial response rate of 54.3% in the carfilzomib arm, compared with 28.6% in the bortezomib arm. More patients in the carfilzomib arm achieved a complete response compared with patients in the bortezomib arm (12.5% vs. 6.2%).

Researchers recorded 75 deaths in carfilzomib arm and 88 deaths in the bortezomib arm at the interim analysis and continue to monitor OS data.

A similar percentage of patients in the carfilzomib and bortezomib arms discontinued treatment due to adverse events (14% vs. 15.7%). Mortality related to adverse events occurred in similar numbers in both groups (3.9% vs. 3.4%).

However, patients treated with carfilzomib remained on treatment significantly longer than patients treated with bortezomib (40 weeks vs. 27 weeks).

Hypertension (8.9% vs. 2.6%), dyspnea (5.6% vs. 2.2%), cardiac failure (4.8% vs. 1.8%) and acute renal failure (4.1% vs. 2.6%) were the most commonly reported grade 3 or higher adverse events.

Researchers observed that low-grade (≥ 2) peripheral neuropathy rates were significantly lower in the carfilzomib arm (6.3% vs. 32%; P < .0001).

Based on the results of the interim analysis, researchers reported that carfilzomib is a potential best-in-class agent for the treatment of relapsed multiple myeloma.

“Carfilzomib is superior to bortezomib regardless of age or prior bortezomib exposure,” Dimopoulos said. “It represents a new standard of care.” – by Cameron Kelsall

Reference:

Dimopoulos MA, et al. Abstract 8509. Presented at: ASCO Annual Meeting; May 29-June 2, 2015; Chicago.

Disclosure: The study was funded by Onyx Pharmaceuticals. Dimopoulos reports honoraria from and a consultant role with Celgene and Onyx Pharmaceuticals. Please see the abstract for a list of all other researchers’ relevant financial disclosures.